Investor Relations

Corporate Overview

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.

Featured Presentation

View All Presentations

Upcoming Events

View All Events

Latest News

View All News

Quick Links

Investor Email Alerts